Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AC Immune's tau-targeted vaccine in early Alzheimer's disease has completed and posted results, assessing safety, tolerabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment
• Dementia

Drugs mentioned

• ACI-35.030 Tau Vaccine (ACI-35.030)

Snippet

Sponsor: AC Immune SA | Conditions: Alzheimer's Disease, Cognitive Impairment | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-14